Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012

[1]  M. Chamberlain,et al.  Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. , 2018, The Lancet. Oncology.

[2]  J. Lunceford,et al.  IFN-&ggr;–related mRNA profile predicts clinical response to PD-1 blockade , 2017, The Journal of clinical investigation.

[3]  D. D. de Alwis,et al.  Evaluation of dosing strategy for pembrolizumab for oncology indications , 2017, Journal of Immunotherapy for Cancer.

[4]  T. Seiwert,et al.  Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Lunceford,et al.  Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. , 2017, The Lancet. Oncology.

[6]  M. Dolled-Filhart,et al.  Development of a Companion Diagnostic for Pembrolizumab in Non-Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1. , 2016, Archives of pathology & laboratory medicine.

[7]  M. Dolled-Filhart,et al.  Development of a Prototype Immunohistochemistry Assay to Measure Programmed Death Ligand-1 Expression in Tumor Tissue. , 2016, Archives of pathology & laboratory medicine.

[8]  R. Berger,et al.  Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Lunceford,et al.  Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. , 2016, The Lancet. Oncology.

[10]  J. Lunceford,et al.  Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. , 2016, The Lancet. Oncology.

[11]  T. Seiwert,et al.  Preliminary results from KEYNOTE-055: Pembrolizumab after platinum and cetuximab failure in head and neck squamous cell carcinoma (HNSCC). , 2016 .

[12]  J. Ahn,et al.  Pembrolizumab for the treatment of non-small cell lung cancer , 2016, Expert opinion on biological therapy.

[13]  J. Radford.  Nivolumab for recurrent squamous-cell carcinoma of the head and neck , 2016, BDJ.

[14]  Ulrich Keilholz,et al.  Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. , 2015, The Lancet. Oncology.

[15]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[16]  J. Wolchok,et al.  Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and IPI-naive (IPI-N) melanoma (MEL). , 2014 .

[17]  Antoni Ribas,et al.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.

[18]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[19]  J. Machiels,et al.  Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. , 2011, The Lancet. Oncology.

[20]  J. Pignon,et al.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[21]  N. Hanna.  Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy , 2008 .

[22]  K. Omura,et al.  Predominant expression of B7-H1 and its immunoregulatory roles in oral squamous cell carcinoma. , 2006, Oral oncology.

[23]  Tasuku Honjo,et al.  PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells , 2004, Cancer Research.

[24]  J. Cheville,et al.  B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. , 2003, Cancer research.

[25]  Xiang Guo,et al.  Head and neck cancers. , 2003, Cancer chemotherapy and biological response modifiers.

[26]  Yoshimasa Tanaka,et al.  Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[27]  G. Freeman,et al.  PD-L2 is a second ligand for PD-1 and inhibits T cell activation , 2001, Nature Immunology.

[28]  G. Freeman,et al.  Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.